Form 4: Glaukos Corp Director Leana Wen Reports Stock and Option Grants

Director Leana Wen reported the acquisition of restricted stock units and stock options in Glaukos Corporation on May 30, 2024.

Summary

• On May 30, 2024, Leana Wen, a director of Glaukos Corporation, reported the acquisition of 1,716 restricted stock units and 1,246 stock options.
• The restricted stock units were granted pursuant to the Issuer's Director Compensation Policy and will vest in full on the one-year anniversary of the grant date, payable in an equivalent number of shares of Glaukos' common stock.
• The stock options, also granted under the Director Compensation Policy, vest in full on the one-year anniversary of the grant date and have an exercise price of $110.7.
• Following these transactions, Wen beneficially owns 18,247 shares of common stock and 1,246 stock options.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive as it reflects standard director compensation practices, aligning interests with shareholders.

Positives

• The grant of restricted stock units and stock options aligns the director's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the director.

Future Outlook

The restricted stock units will vest in full on the one-year anniversary of the grant date and are payable in an equivalent number of shares of the Issuer's common stock. The stock options vest in full on the one-year anniversary of the grant date.

Industry Context

Director compensation through stock grants and options is a common practice in publicly traded companies to align management's interests with shareholders.

Comparison to Industry Standards

• Stock option grants are a typical component of executive compensation packages in the medical device industry, often benchmarked against peer companies of similar size and market capitalization.
• Vesting schedules, such as the one-year vesting period for these grants, are also standard practice to incentivize long-term performance and retention.
• Comparable companies in the ophthalmic medical device space, such as STAAR Surgical or Aerie Pharmaceuticals, also utilize stock options and restricted stock units as part of their director compensation plans.

Stakeholder Impact

• The stock and option grants align the director's interests with those of the shareholders, potentially leading to decisions that benefit the company's long-term value.
• Employees may view the grants as a positive sign of the company's commitment to its leadership.

Key Dates